Rapid diagnosis and treatment response in immune therapy-related kidney injury
Official title: Rapid Diagnosis and Treatment Response Phenotyping of Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis
Funded at Yale University · NIH-11369158 · Data updated 2026-11-12
A study to find real-time biomarkers to diagnose ICI-related kidney injury and predict whether steroids will work, so patients on cancer immunotherapy get faster, better treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | August 10, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,407,724 |
| NIH project number | 4R01DK140717-03 |
| Project ID | NIH-11369158 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients on immune checkpoint inhibitor therapy who develop AKI or kidney injury while receiving treatment.
✕Less likely to help
Patients without kidney injury or those not on immune checkpoint inhibitors may not benefit from this study.
What this research studies
If you are being treated with immune checkpoint inhibitors for cancer and develop kidney problems, this study tests a biomarker called CXCL9 to help confirm whether the injury is related to the cancer therapy and to predict response to steroids. The researchers will enroll up to 400 participants across three major hospitals, including 100 with ICI-associated nephritis, and track how well kidney function improves with therapy. They will also use advanced proteomics to understand why some patients don’t respond to corticosteroids and to identify better second-line treatments. This work aims to speed diagnosis, tailor treatments, and reduce kidney-related complications for people receiving cancer immunotherapy.
Why it matters
Potential benefit: If successful, patients could receive faster, more accurate diagnoses and more effective treatment plans for kidney injury related to cancer immunotherapy.
How similar studies have gone: Previous work has explored biomarkers for kidney injury, but this project tests a real-time biomarker (CXCL9) specifically for ICI-associated nephritis and treatment response.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Moledina, Dennis G. — Yale University
- Study coordinator: Moledina, Dennis G.
Related research
Other NIH-funded projects on the same topics.
-
Autoimmune diabetes linked to cancer immunotherapy: discovering causes and biomarkers
This grant explores why some people on cancer immunotherapy develop autoimmune diabetes and aims to find biomarkers to predict and prevent it.
-
ctDNA biomarker to guide safety of cancer immunotherapy in inflammatory arthritis
A patient-facing biomarker study using a blood test to detect tumor DNA in people with cancer who develop inflammatory arthritis from immunotherapy, to help doctors pick safer treatment choices.
-
Cross-species study of immune responses to cancer immunotherapy in dogs and humans with invasive bladder cancer
A study using dogs with naturally occurring invasive bladder cancer to help improve immune checkpoint therapies for people with the same disease.
-
Characterizing the psychological symptoms in melanoma patients on immunotherapy
A long-term study follows adults with advanced skin cancer who are starting immune checkpoint therapy to understand the pattern of emotional and psychological symptoms they experience.
-
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor–Associated Heart Inflammation
A doctor-scientist team is studying why cancer patients treated with immune checkpoint drugs sometimes develop dangerous heart inflammation and what immune targets cause it.
-
Pathway-guided treatment of colon toxicity from immune checkpoint inhibitors
A patient-focused look at a study that aims to understand and improve how immune checkpoint inhibitor therapy causes colon inflammation and how to treat it more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.